Pandemic and All-Hazards Preparedness Reauthorization Act of 2013

This bill reauthorizes and updates the Pandemic and All-Hazards Preparedness Act (PAHPA) of 2006, which established the Assistant Secretary for Preparedness and Response (ASPR) and provided a framework for national preparedness for public health emergencies. The reauthorization ensures continued funding for the Biomedical Advanced Research and Development Authority (BARDA), the Strategic National Stockpile (SNS), and other programs critical for developing and procuring medical countermeasures. This directly impacts companies involved in vaccine development, therapeutic manufacturing, and emergency medical supplies by providing a stable demand signal and funding for research and development. The money trail for this legislation primarily flows through BARDA, which awards contracts and grants for the development of medical countermeasures. The SNS procures vaccines, therapeutics, and medical supplies from pharmaceutical and medical device companies. Specific companies positioned to receive contracts include major pharmaceutical firms like Johnson & Johnson ($JNJ), Pfizer ($PFE), and Merck ($MRK), which are active in vaccine and therapeutic development. Companies involved in medical supplies and diagnostics, such as Becton, Dickinson and Company ($BDX) and Abbott Laboratories ($ABT), also benefit. Healthcare service providers like CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) are involved in distribution and administration, and staffing companies like AMN Healthcare Services ($AMN) support emergency response. Historically, the original PAHPA in 2006 created a sustained market for biodefense and emergency preparedness products. Following its enactment, companies like Emergent BioSolutions ($EBS), a key anthrax vaccine provider, saw consistent government contracts. While specific stock movements tied directly to the 2006 bill's passage are difficult to isolate due to broader market conditions, the legislation established a predictable funding stream that supported long-term R&D and procurement in the sector. The 2013 reauthorization continued this trend, providing stability rather than a sudden surge. For example, when the 2006 act was passed, companies focused on biodefense saw a more stable revenue outlook, which supported their stock valuations over the subsequent years. Specific winners include pharmaceutical companies with established emergency preparedness portfolios like Johnson & Johnson ($JNJ), Pfizer ($PFE), and Merck ($MRK). Gilead Sciences ($GILD) also benefits through its antiviral development. Medical device and diagnostic companies such as Becton, Dickinson and Company ($BDX) and Thermo Fisher Scientific ($TMO) see continued demand for their products. Losers are not directly identifiable, as this bill represents a continuation of existing policy and funding rather than a reduction or redirection. This bill has been read twice and referred to committee. The next step is committee consideration, including hearings and potential amendments. If approved by the committee, it moves to the full Senate for a vote, then to the House for consideration. The reauthorization process typically involves bipartisan support due to its public health nature, indicating a high probability of eventual passage. The impact on companies will be the continuation of existing contract opportunities and R&D funding, not a new market creation.